Fracture – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 0 PAGES: 47

More Info
									                               Fracture – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1819IDB
                                                                                             Publication Date: March 2012




Fracture – Pipeline Review, H1 2012                                                         GMDHC1819IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(1)
Fracture – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Fracture Overview .............................................................................................................................................................................. 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Fracture .............................................................................................................................. 7
Fracture Therapeutics under Development by Companies ................................................................................................................ 9
Fracture Therapeutics under Investigation by Universities/Institutes................................................................................................ 10
Late Stage Products ......................................................................................................................................................................... 11
    Comparative Analysis .................................................................................................................................................................. 11
Mid Clinical Stage Products.............................................................................................................................................................. 12
    Comparative Analysis .................................................................................................................................................................. 12
Early Clinical Stage Products ........................................................................................................................................................... 13
    Comparative Analysis .................................................................................................................................................................. 13
Fracture Therapeutics – Products under Development by Companies ............................................................................................ 14
Fracture Therapeutics – Products under Investigation by Universities/Institutes.............................................................................. 15
Companies Involved in Fracture Therapeutics Development ........................................................................................................... 16
    Amgen Inc. .................................................................................................................................................................................. 16
    Eli Lilly and Company .................................................................................................................................................................. 17
    Kaken Pharmaceutical Co.,Ltd. ................................................................................................................................................... 18
    Radius Health, Inc. ...................................................................................................................................................................... 19
Fracture – Therapeutics Assessment ............................................................................................................................................... 20
    Assessment by Monotherapy Products ....................................................................................................................................... 20
    Assessment by Route of Administration ...................................................................................................................................... 21
    Assessment by Molecule Type .................................................................................................................................................... 23
Drug Profiles..................................................................................................................................................................................... 25
    AMG 785 - Drug Profile ............................................................................................................................................................... 25
         Product Description................................................................................................................................................................. 25
         Mechanism of Action ............................................................................................................................................................... 25
         R&D Progress ......................................................................................................................................................................... 25
    KUR-111 - Drug Profile ................................................................................................................................................................ 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ............................................................................................................................................................... 26
         R&D Progress ......................................................................................................................................................................... 26
    KCB-1B - Drug Profile ................................................................................................................................................................. 28
         Product Description................................................................................................................................................................. 28
         Mechanism of Action ............................................................................................................................................................... 28
         R&D Progress ......................................................................................................................................................................... 28
    Drug For Bone Healing - Drug Profile .......................................................................................................................................... 29
         Product Description................................................................................................................................................................. 29



Fracture – Pipeline Review, H1 2012                                                                                                             GMDHC1819IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Fracture – Pipeline Review, H1 2012




         Mechanism of Action ............................................................................................................................................................... 29
         R&D Progress ......................................................................................................................................................................... 29
    BA058 - Drug Profile.................................................................................................................................................................... 30
         Product Description................................................................................................................................................................. 30
         Mechanism of Action ............................................................................................................................................................... 30
         R&D Progress ......................................................................................................................................................................... 30
    Testosterone gel - Drug Profile .................................................................................................................................................... 32
         Product Description...............................................................................................................................................
								
To top